Sentry Investment Management LLC Has $432,000 Stake in DexCom, Inc. $DXCM

Sentry Investment Management LLC raised its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 54.3% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 5,157 shares of the medical device company’s stock after purchasing an additional 1,815 shares during the period. Sentry Investment Management LLC’s holdings in DexCom were worth $432,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in DXCM. Nuveen LLC acquired a new position in DexCom during the 1st quarter valued at about $554,893,000. Jennison Associates LLC boosted its stake in DexCom by 37.7% during the 1st quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company’s stock valued at $718,632,000 after purchasing an additional 2,879,489 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in DexCom by 171.0% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 3,194,829 shares of the medical device company’s stock valued at $218,175,000 after purchasing an additional 2,015,971 shares during the last quarter. Federated Hermes Inc. boosted its stake in DexCom by 2,371.4% during the 1st quarter. Federated Hermes Inc. now owns 1,994,732 shares of the medical device company’s stock valued at $136,220,000 after purchasing an additional 1,914,019 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in DexCom by 22.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock valued at $691,336,000 after purchasing an additional 1,868,241 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Trading Up 0.4%

NASDAQ:DXCM opened at $66.60 on Monday. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $26.12 billion, a PE ratio of 46.25, a price-to-earnings-growth ratio of 1.40 and a beta of 1.47. The firm’s 50 day moving average is $73.35 and its 200 day moving average is $77.69. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $93.25.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.45 by $0.03. The company had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. DexCom’s revenue was up 15.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. Sell-side analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Activity at DexCom

In related news, EVP Sadie Stern sold 1,466 shares of DexCom stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $80.00, for a total value of $117,280.00. Following the sale, the executive vice president owned 105,223 shares of the company’s stock, valued at approximately $8,417,840. The trade was a 1.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $80.29, for a total transaction of $40,145.00. Following the completion of the sale, the executive vice president directly owned 94,102 shares in the company, valued at $7,555,449.58. This trade represents a 0.53% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 6,849 shares of company stock worth $564,733. Company insiders own 0.32% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on DXCM shares. Argus began coverage on DexCom in a research note on Thursday, August 21st. They set a “buy” rating and a $100.00 price target for the company. Morgan Stanley boosted their target price on DexCom from $82.00 to $89.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. Wall Street Zen downgraded DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, August 10th. Raymond James Financial boosted their target price on DexCom from $99.00 to $102.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 31st. Finally, UBS Group boosted their target price on DexCom from $105.00 to $106.00 and gave the stock a “buy” rating in a research note on Thursday, July 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $97.00.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.